Add to ORKGUrinary bladder cancer is a relatively common condition. A significant proportion of intermediate and highly malignant tumors recur and progress to invasive cancer. Various pharmaceutical agents have been tested in different regimens of intravesical treatment to prevent recurrence and progression. Currently, the standard treatment for non-invasive bladder cancers is the immediate, -after complete tumor resection- injection of a chemotherapeutic agent. For patients at intermediate-risk, a series of intravesical chemotherapy or immunotherapy for a 6-week period is suggested
Intravesical chemo/immunotherapy is a constituent of combination treatment for bladder cancer and wi...
We retrospectively evaluated the efficacy of immediate single instillation (SI) of pirarubicine hydr...
Objectives: Intravesical chemotherapy has been studied in randomized clinical trials for >30 yr; how...
Urinary bladder cancer is a relatively common condition. A significant proportion of intermediate an...
Bladder cancer is the second most common tumor among all neoplasms of the genitourinary tract in the...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Non-muscle invasive bladder cancer tends to recur after transurethral resection (TUR) and an intrave...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacit...
BACKGROUND: Tumor recurrence is the most expected clinical event after the resection of non-muscle ...
Bladder cancer treatment remains a challenge despite significant improvements in preventing disease ...
Transurethral resection (TUR) of the superficial transitional cell carcinoma (TCC) of the bladder is...
Bladder cancer represents the second most common neoplasm of the urinary tract and the fourth in gen...
Non-muscle-invasive bladder cancer is a highly recurrent disease. The health care costs for non-musc...
According to clinical and pathological factors the prognosis of a patient with non-muscle invasive b...
Intravesical chemo/immunotherapy is a constituent of combination treatment for bladder cancer and wi...
We retrospectively evaluated the efficacy of immediate single instillation (SI) of pirarubicine hydr...
Objectives: Intravesical chemotherapy has been studied in randomized clinical trials for >30 yr; how...
Urinary bladder cancer is a relatively common condition. A significant proportion of intermediate an...
Bladder cancer is the second most common tumor among all neoplasms of the genitourinary tract in the...
Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle i...
Non-muscle invasive bladder cancer tends to recur after transurethral resection (TUR) and an intrave...
Background: In 2002 there were estimated to be 357,000 new cases of bladder cancer worldwide and 14...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a tendency for recurrence and capacit...
BACKGROUND: Tumor recurrence is the most expected clinical event after the resection of non-muscle ...
Bladder cancer treatment remains a challenge despite significant improvements in preventing disease ...
Transurethral resection (TUR) of the superficial transitional cell carcinoma (TCC) of the bladder is...
Bladder cancer represents the second most common neoplasm of the urinary tract and the fourth in gen...
Non-muscle-invasive bladder cancer is a highly recurrent disease. The health care costs for non-musc...
According to clinical and pathological factors the prognosis of a patient with non-muscle invasive b...
Intravesical chemo/immunotherapy is a constituent of combination treatment for bladder cancer and wi...
We retrospectively evaluated the efficacy of immediate single instillation (SI) of pirarubicine hydr...
Objectives: Intravesical chemotherapy has been studied in randomized clinical trials for >30 yr; how...